Works by ZHONG Lai-ping


Results: 44
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.

    Published in:
    Cancer Communications, 2021, v. 41, n. 3, p. 279, doi. 10.1002/cac2.12136
    By:
    • Ju, Wu‐tong;
    • Liu, Ying;
    • Wang, Li‐zhen;
    • Li, Jiang;
    • Ren, Guo‐xing;
    • Sun, Jian;
    • Tu, Wen‐yong;
    • Hu, Yong‐jie;
    • Ji, Tong;
    • Yang, Wen‐jun;
    • Li, Jun;
    • He, Yue;
    • Wang, Yan‐an;
    • Zhang, Chen‐ping;
    • Zhong, Lai‐ping;
    • Zhang, Zhi‐yuan
    Publication type:
    Article
    38
    39
    40
    41

    A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-33080-8
    By:
    • Ju, Wu-tong;
    • Xia, Rong-hui;
    • Zhu, Dong-wang;
    • Dou, Sheng-jin;
    • Zhu, Guo-pei;
    • Dong, Min-jun;
    • Wang, Li-zhen;
    • Sun, Qi;
    • Zhao, Tong-chao;
    • Zhou, Zhi-hang;
    • Liang, Si-yuan;
    • Huang, Ying-ying;
    • Tang, Yong;
    • Wu, Si-cheng;
    • Xia, Jing;
    • Chen, Shi-qing;
    • Bai, Yue-zong;
    • Li, Jiang;
    • Zhu, Qi;
    • Zhong, Lai-ping
    Publication type:
    Article
    42
    43
    44